Division of Clinical Sciences

Not signed in
Sign in

Powered by Sitebuilder
© MMXII | Privacy
Accessibility

3rd International Symposium

Scientific Board

Laura Biron, Johns Hopkins, Washington DC - Health Impact Fund; Zameel Cader, Oxford - New variants for migraine; Aileen Clarke, Warwick Evidence, Personalising evidenced-based decisions; Wendy L Currie, Warwick - eHealth; Alan Davies, CMO EMEA, GE Healthcare - Diagnostics and HCIT in earlier diagnosis, targeted therapy and monitoring; Arun Dheer, UHCW, Coventry - Integrated Healthcare; Sir Gordon Duff, Chairman, UK Commission on Human Medicines - Personalised Healthcare: Luxury or Necessity?; Adam Heathfield, Director of Science Policy for Europe, Pfizer - Development of Personalised Treatment; Andrew Marsh, Warwick, Chemical Genomics; Munir Pirmohamed, Liverpool - Filling the translational gaps; Miquel Pons, Barcelona, drug discovery; Dan Rathbone, Aston, Drug Discovery; Philip Routledge, Cardiff - Regulatory perspectives; Duane Schulthess, Commercial Director, Science|Business, Brussels, policy on health innovation; Andrew Shindler, London, Intellectual Property; Donald Singer, Warwick - new target discovery

Key themes	Of interest to
biologicals	biotechnology industry
biomarkers	chemical biologists
ethical issues	ethicists
explaining risk	experts in intellectual property and patents
genetic variability in drug response	geneticists
health inequality resolution	health economists
eHealth systems	health media
genetic markers of response	health professionals
genetic markers of risk	pharmacologists
new approaches to drug discovery	pharmaceutical professionals
pharmacogenomic testing	policy makers and advisers
regulatory perspectives	prescribers
RNA therapeutics	regulatory authorities
safer prescribing	scientists interested in new therapeutic targets
stem cell therapy	scientists interested in drug development
view from policy makers	scientists interested in diversity in clinical response to medicines